The DOI matches its Crossref record; the references it cites are not checked yet.
ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials
Abstract
Alterations in lipid metabolism might contribute to the pathogenesis of non-alcoholic fatty liver disease (NAFLD). However, no pharmacological agents are currently approved in the United States or the European Union for the treatment of NAFLD. Two parallel phase 2a studies investigated the effects of liver-directed ACC1/2 inhibition in adults with NAFLD. The first study ( NCT03248882 ) examined the effects of monotherapy with a novel ACC1/2 inhibitor, PF-05221304 (2, 10, 25 and 50 mg once daily (QD)), versus placebo at 16 weeks of treatment; the second study ( NCT03776175 ) investigated the effects of PF-05221304 (15 mg twice daily (BID)) co-administered with a DGAT2 inhibitor, PF-06865571 (300 mg BID), versus placebo after 6 weeks of treatment. The primary endpoint in both studies was percent change from baseline in liver fat assessed by magnetic resonance imaging-proton density fat fraction. Dose-dependent reductions in liver fat reached 50-65% with PF-05221304 monotherapy doses ≥10 mg QD; least squares mean (LSM) 80% confidence interval (CI) was -7.2 (-13.9, 0.0), -17.1 (-22.7, -11.1), -49.9 (-53.3, -46.2), -55.9 (-59.0, -52.4) and -64.8 (-67.5, -62.0) with 16 weeks placebo and PF-05221304 2, 10, 25 and 50 mg QD, respectively. The overall incidence of adverse events (AEs) did not increase with increasing PF-05221304 dose, except for a dose-dependent elevation in serum triglycerides (a known consequence of hepatic acetyl-coenzyme A carboxylase (ACC) inhibition) in 23/305 (8%) patients, leading to withdrawal in 13/305 (4%), and a dose-dependent elevation in other serum lipids. Co-administration of PF-05221304 and PF-06865571 lowered liver fat compared to placebo (placebo-adjusted LSM (90% CI) -44.6% (-54.8, -32.2)). Placebo-adjusted LSM (90% CI) reduction in liver fat was -44.5% (-55.0, -31.7) and -35.4% (-47.4, -20.7) after 6 weeks with PF-05221304 or PF-06865571 alone. AEs were reported for 10/28 (36%) patients after co-administered PF-05221304 and PF-06865571, with no discontinuations due to AEs, and the ACC inhibitor-mediated effect on serum triglycerides was mitigated, suggesting that PF-05221304 and PF-06865571 co-administration has the potential to address some of the limitations of ACC inhibition alone.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“| Loomba et al. | Firsocostat (=GS-0976) | NAFLD | PDFF -3.5 %; fibrosis ↔ | ↔ | ↔ | TG↑; HDL ↔; LDL | NR |”
From Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? (2024) · cites this paper as [222]
In the citing paper
“| Loomba et al. | Firsocostat (=GS-0976) | NAFLD | PDFF -3.5 %; fibrosis ↔ | ↔ | ↔ | TG↑; HDL ↔; LDL | NR |”
From Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? (2024) · cites this paper as [222]
In the citing paper
“| Loomba et al. | Firsocostat (=GS-0976) | NAFLD | PDFF -3.5 %; fibrosis ↔ | ↔ | ↔ | TG↑; HDL ↔; LDL | NR |”
From Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? (2024) · cites this paper as [222]
In the citing paper
“As such, combination therapy with the DGAT2 inhibitor Ervogastat and Clesacostat, an inhibitor of Acetyl-CoA Carboxylase (ACC, also a downstream rate-limiting enzyme in de novo lipogenesis) was granted fast track designation by the FDA for the treatment of non-alcoholic steatohepatitis (NASH) with liver fibrosis, based on its favorable safety and tolerability profile in a Phase2a clinical trial.86”
From Amyloid-β induces lipid droplet-mediated microglial dysfunction via the enzyme DGAT2 in Alzheimer’s disease (2025) · cites this paper as [86]
In the citing paper
“Dgat2 and Gpam are critical enzymes in triglyceride synthesis, and Dgat2 is currently being inhibited in NASH clinical trials15,16.”
From Positive selection of somatically mutated clones identifies adaptive pathways in metabolic liver disease (2023) · cites this paper as [15]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
The citation lists are queued
They are fetched later and appear here then.
References 50 · Cited by 219
Research works printed but not linked: 1
- Saxena, A., Chidsey, K., Somayaji, V., Ogden, A. & Duvvuri, S. Diacylglycerol acyltransferase 2 (DGAT2) inhibitor PF-06865571 reduces liver fat by MRI–PDFF after 2 weeks in adults with NAFLD. Hepatology 70, 1260A (2019).
Metadata
- Authors
- Calle, R. A., Amin, N. B., Carvajal-Gonzalez, S., Ross, T. T., Bergman, A., Aggarwal, S., Crowley, C., Rinaldi, A., Mancuso, J., Aggarwal, N., Somayaji, V., Inglot, M., Tuthill, T. A., Kou, K., Boucher, M., Tesz, G., Dullea, R., Bence, K. K., Kim, A. M., Pfefferkorn, J. A., & Esler, W. P.
- Affiliations
- Pfizer (United States) (US)
- Corresponding author
- Esler, William P.
- ORCID
- Venue
- Nature Medicine
- Published
- 2021-10
- Volume
- 27
- Issue
- 10
- Pages
- 1836-1848
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W3205941711
- Cited by
- 219
- References
- 50
- Citations by year
- 2026: 23 · 2025: 53 · 2024: 51 · 2023: 48 · 2022: 38 · 2021: 5
- FWCI
- 25.55
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Pfizer
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- non-alcoholic fatty liver disease, acetyl-CoA carboxylase inhibition, liver fat reduction, proton density fat fraction, serum triglycerides, lipid metabolism, combination therapy, dose escalation, adverse events
- MeSH terms
- Acetyl-CoA Carboxylase, Double-Blind Method, Drug Synergism, Enzyme Inhibitors, Female, Humans, Liver, Magnetic Resonance Imaging, Male, Middle Aged, Placebos, Lipid Metabolism, Diacylglycerol O-Acyltransferase, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials. https://app.cochat.ai/papers/10.1038/s41591-021-01489-1
- The paper
- Calle, R. A., Amin, N. B., Carvajal-Gonzalez, S., Ross, T. T., Bergman, A., Aggarwal, S., Crowley, C., Rinaldi, A., Mancuso, J., Aggarwal, N., Somayaji, V., Inglot, M., Tuthill, T. A., Kou, K., Boucher, M., Tesz, G., Dullea, R., Bence, K. K., Kim, A. M., . . . Esler, W. P. (2021). ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials. Nature Medicine. https://doi.org/10.1038/s41591-021-01489-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.